Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
High-profile lawsuits and SEC investigations over cash sweeps have taken the industry by storm.
Spurred by “the rise of Chinese power,” Japanese automakers Honda and Nissan announced Monday that they are in talks to merge.
The secret ingredients to Lego’s success? A clutch of licensing deals and finding ways to sell Lego sets to kids well over the age of 30.